Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Encorafenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 22,998Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer's Braftovi+Mektovi Demonstrates Prolonged Survival
    Pfizer's Braftovi+Mektovi Demonstrates Prolonged Survival

    22 Oct 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/clinical-trials/pfizers-braftovimektovi-shows-sustained-long-term-survival-in-patients-with-advanced-lung-cancer-18042

    INDPHARMAPOST
    22 Oct 2025
    Share Share
    Pfizer's Braftovi + Mektovi Sustain Long-Term Survival in Cancer
    Pfizer's Braftovi + Mektovi Sustain Long-Term Survival in Cancer

    19 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-19/pfizer-s-braftovi-plus-mektovi-shows-sustained-long-term-survival-in-patients-with-advanced-lung-canc

    PHARMIWEB
    19 Oct 2025
    Share Share
    Pfizer’s Braftovi Combo Halves Death Risk In Colorectal Cancer
    Pfizer’s Braftovi Combo Halves Death Risk In Colorectal Cancer

    30 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250530872619/en/Pfizers-BRAFTOVI-Combination-Regimen-Cuts-the-Risk-of-Death-in-Half-for-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    30 May 2025
    Share Share
    Pfizer's Vision for Cancer Care at ASCO 2025 Meeting
    Pfizer's Vision for Cancer Care at ASCO 2025 Meeting

    23 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250423613410/en/Pfizer-Advances-Bold-Vision-for-Future-of-Cancer-Care-at-the-ASCO-2025-Annual-Meeting

    BUSINESSWIRE
    23 Apr 2025
    Share Share
    Pfizer angles Braftovi combo for full FDA approval
    Pfizer angles Braftovi combo for full FDA approval

    04 Feb 2025

    // PRESS RELEASE

    https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovir-combination-regimen-significantly

    PRESS RELEASE
    04 Feb 2025
    Share Share
    Pfizer’s BRAFTOVI Boosts Response In Mutant Colorectal Cancer
    Pfizer’s BRAFTOVI Boosts Response In Mutant Colorectal Cancer

    27 Jan 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/pfizers-braftovi-combination-demonstrates-improved-response-for-mutant-metastatic-colorectal-cancer-16710

    INDPHARMAPOST
    27 Jan 2025
    Share Share